Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial

Jürgen Behr, Maurits Demedts, Roland Buhl, Ulrich Costabel, Richard P N Dekhuijzen, Henk M Jansen, William MacNee, Michiel Thomeer, Benoit Wallaert, Francois Laurent, Andrew G Nicholson, Eric K Verbeken, Johny Verschakelen, C D R Flower, Stefano Petruzzelli, Paul De Vuyst, J M M van den Bosch, Eulogio Rodriguez-Becerra, Ida Lankhorst, Marco Sardina, Gabrielle Boissard, IFIGENIA study group, M Demedts, J Behr, R Buhl, U Costabel, P N R Dekhuijzen, H M Jansen, W MacNee, B Wallaert, M Thomeer, C D R Flower, F Laurent, J Verschakelen, A G Nicholson, E K Verbeken, F Capron, J Behr, J M M van den Bosch, P De Vuyst, E Rodriguez-Becerra, S Petruzzelli, B Wallaert, G Corvasce, A Peviani, I Lankhorst, E Makin, L Licciardello, S Bellinvia, C Di Padova, M Sardina, N Kormoss, P Boulanger, A Esteras, F Sirtori, G Moroni, G Boissard, A Ardia, M Montanari, M Demedts, M Thomeer, U Z Gasthuisberg, H Slabbynck, E Michiels, P De Vuyst, B Wallert, N Just, J F Muir, Ph Delaval, P Chanez, A Bourdin, J Cadranel, Ph Camus, U Costabel, H Steveling, J Behr, R Baumgartner, R Buhl, J Müller-Quernheim, R Loddenkemper, T Welte, A Meyer, R Bonnet, I Mäder, G Simon, G Bottino, C Giuntini, A Rossi, S Gasparini, M Dottorini, G Anzalone, G Bustacchini, E Rodríguez-Becerra, L Callol Sanchez, J Ancochea Bermudez, J M Rodriguez-Arias, I Vigil, J L Llorente, J van den Bosch, F Beaumont, H M Jansen, F J J van den Elshout, M Drent, Jürgen Behr, Maurits Demedts, Roland Buhl, Ulrich Costabel, Richard P N Dekhuijzen, Henk M Jansen, William MacNee, Michiel Thomeer, Benoit Wallaert, Francois Laurent, Andrew G Nicholson, Eric K Verbeken, Johny Verschakelen, C D R Flower, Stefano Petruzzelli, Paul De Vuyst, J M M van den Bosch, Eulogio Rodriguez-Becerra, Ida Lankhorst, Marco Sardina, Gabrielle Boissard, IFIGENIA study group, M Demedts, J Behr, R Buhl, U Costabel, P N R Dekhuijzen, H M Jansen, W MacNee, B Wallaert, M Thomeer, C D R Flower, F Laurent, J Verschakelen, A G Nicholson, E K Verbeken, F Capron, J Behr, J M M van den Bosch, P De Vuyst, E Rodriguez-Becerra, S Petruzzelli, B Wallaert, G Corvasce, A Peviani, I Lankhorst, E Makin, L Licciardello, S Bellinvia, C Di Padova, M Sardina, N Kormoss, P Boulanger, A Esteras, F Sirtori, G Moroni, G Boissard, A Ardia, M Montanari, M Demedts, M Thomeer, U Z Gasthuisberg, H Slabbynck, E Michiels, P De Vuyst, B Wallert, N Just, J F Muir, Ph Delaval, P Chanez, A Bourdin, J Cadranel, Ph Camus, U Costabel, H Steveling, J Behr, R Baumgartner, R Buhl, J Müller-Quernheim, R Loddenkemper, T Welte, A Meyer, R Bonnet, I Mäder, G Simon, G Bottino, C Giuntini, A Rossi, S Gasparini, M Dottorini, G Anzalone, G Bustacchini, E Rodríguez-Becerra, L Callol Sanchez, J Ancochea Bermudez, J M Rodriguez-Arias, I Vigil, J L Llorente, J van den Bosch, F Beaumont, H M Jansen, F J J van den Elshout, M Drent

Abstract

Background: The randomized placebo-controlled IFIGENIA-trial demonstrated that therapy with high-dose N-acetylcysteine (NAC) given for one year, added to prednisone and azathioprine, significantly ameliorates (i.e. slows down) disease progression in terms of vital capacity (VC) (+9%) and diffusing capacity (DLco) (+24%) in idiopathic pulmonary fibrosis (IPF). To better understand the clinical implications of these findings we performed additional, explorative analyses of the IFGENIA data set.

Methods: We analysed effects of NAC on VC, DLco, a composite physiologic index (CPI), and mortality in the 155 study-patients.

Results: In trial completers the functional indices did not change significantly with NAC, whereas most indices deteriorated with placebo; in non-completers the majority of indices worsened but decline was generally less pronounced in most indices with NAC than with placebo. Most categorical analyses of VC, DLco and CPI also showed favourable changes with NAC. The effects of NAC on VC, DLco and CPI were significantly better if the baseline CPI was 50 points or lower.

Conclusion: This descriptive analysis confirms and extends the favourable effects of NAC on lung function in IPF and emphasizes the usefulness of VC, DLco, and the CPI for the evaluation of a therapeutic effect. Most importantly, less progressed disease as indicated by a CPI of 50 points or lower at baseline was more responsive to therapy in this study.

Trial registration: ClinicalTrials.gov NCT00639496.

Figures

Figure 1
Figure 1
Categorical analyses in steps of 5% change from baseline during the one year study period. a: VC: Higher percentages of patients receiving NAC (black columns) showed any improvement and improvement of 5% or more as compared to baseline, whereas higher percentages of patients receiving placebo (white columns) showed any deterioration or decreases of VC of more than 5, 10, 15, 20, and 25% from baseline; this difference was significant at the 5% level (* p < 0.05 NAC vs plac). b: DLco#: A higher percentage of patients receiving NAC (black columns) showed improvement and a lower percentage of patients receiving NAC (black columns) showed deterioration of DLco as compared to placebo (white columns). The differences were statistically significant at the levels <-40%, <-35%, <-5%, >5%, any deterioration, and any improvement (* p < 0.05 NAC vs plac for each of these comparisons). # numbers refer to DLco Hb corrected. c: CPI: A higher percentage of patients receiving NAC (black columns) showed improvement (i.e. decrease) and a lower percentage of patients receiving NAC (black columns) showed deterioration (i.e. increase) of the CPI as compared to placebo (white columns). The differences were statistically not significant.
Figure 2
Figure 2
Effects of NAC on CPI, VC, and DLco, depending on baseline CPI being lower or higher than 50 points. a: Effect of NAC therapy on change in CPI from baseline, depending on baseline CPI being lower or higher than 50 points. Black columns = NAC; white columns = placebo. LS means and 95% confidence interval for changes from baseline in a model including treatment and CPI category as fixed factors are plotted. * p = 0.0002 vs BL-CPI< = 50 NAC. ◆ p = 0.016 vs. BL-CPI< = 50 Placebo b: Effect of NAC therapy on change in VC from baseline, depending on baseline CPI being lower or higher than 50 points. Black columns = NAC; white columns = placebo. LS means and 95% confidence interval for changes from baseline in a model including treatment and CPI category as fixed factors are plotted. * p = 0.0031 vs BL-CPI< = 50 NAC. p = 0.0066 between both NAC subunits. c: Effect of NAC therapy on change in DLco from baseline, depending on baseline CPI being lower or higher than 50 points. Black columns = NAC; white columns = placebo. LS means and 95% confidence interval for changes from baseline in a model including treatment and CPI category as fixed factors are plotted. * p = 0.0015 vs BL-CPI< = 50 NAC. ◆ p = 0.067 vs. BL-CPI< = 50 Placebo.

References

    1. Katzenstein ALA, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157:1301–1315.
    1. Bjoraker JA, Ryu JH, Edwin MH, Myers JL, Tazelaar HD, Schroeder DR, Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157:199–203.
    1. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The clinical significance of reclassifying patients with cryptogenic fibrosing alveolitis according to the histopathological patterns of interstitial pneumonias. Am J Respir Crit Care Med. 2000;162:2213–7.
    1. American Thoracic Society. Idiopathic pulmonary Fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS) Am J Respir Crit Care Med. 2000;161:646–664.
    1. American Thoracic Society. ATS/ERS international multidisciplinary consensus classification of idiopathic interstitial pneumonias. General principes and recommendations. Am J Respir Crit Care Med. 2002;165:277–304.
    1. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med. 2001;345:517–25. doi: 10.1056/NEJMra003200.
    1. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen H, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson A, Verbeken E, Verschakelen J, Flower C, Capron F, Petruzzelli S, De Vuyst P, Bosch J van den, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M. IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353(21):2229–2242. doi: 10.1056/NEJMoa042976.
    1. Behr J, Maier K, Degenholb B, Krombach F, Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med. 1997;156:1897–901.
    1. Hunninghake GW. Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2285–2287. doi: 10.1056/NEJMe058210.
    1. Wells AU, Desai SR, Rubens MB, Goh N, Cramer D, Nicholson A, Colby T, du Bois R, Hansell D. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003;167:962–969. doi: 10.1164/rccm.2111053.
    1. Official Statement of the European Respiratory Society. Standardized lung function testing. Eur Respir J. 1993;6:5–100.
    1. Roca J, Whipp B (chairmen). ERS Task Force on Standardization of Clinical Exercise Testing. Clinical exercise testing with reference to lung disease: indications, standardization and interpretation strategies. Eur Respir J. 1997;10:2662–89. doi: 10.1183/09031936.97.10112662.
    1. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolapopoulou A, Veeraraghavan S, Hansell DM, Wells AU. Fibrotic idiopathic interstitial pneumonia: The prognostic value of longitudinal functional trends. Am J Respir Crit Care Med. 2003;168:531–7. doi: 10.1164/rccm.200210-1245OC.
    1. Watters L, King TE jr, Schwarz M, Waldron JA, Stanford R, Cherniak R. A clinical, radiographic and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1986;133:97–103.
    1. King T Jr, Tooze J, Schwartz M, Brown K, Cherniack R. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respi Crit Care Med. 2001;164:1171–1181.
    1. Gay SE, Kazerooni EA, Toews GB, Lynch J III, Gross BH, Cascade PN, Spizarny DL, Flint A, Schork MA, Whyte RI, Popovich J, Hyzy R, Martinez FJ. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med. 1998;157:1063–72.
    1. Raghu G, Brown K, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE jr. A placebo controlled trial of interferon gamma-1β in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004;350:125–33. doi: 10.1056/NEJMoa030511.
    1. King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu G. BUILD- 1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;177:75–81. doi: 10.1164/rccm.200705-732OC.
    1. Collard HR, King TE jr, Bucher Bartelson B, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168:538–42. doi: 10.1164/rccm.200211-1311OC.
    1. Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, Travis WD, Flint A, Toews GB, Lynch JP, Martinez FJ. Prognostic implications of physiologic and radio-graphic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168:543–8. doi: 10.1164/rccm.200209-1112OC.
    1. Flaherty K, Andrei A, Murray S, Fraley C, Colby T, Travis W, Lama V, Kazerooni E, Gross B, Toews G, Martinez F. Idiopathic Pulmonary Fibrosis: Prognostic Value of Changes in Physiology and Six-Minute-Walk Test. Am J Respir Crit Care Med. 2006;174(7):803–9. doi: 10.1164/rccm.200604-488OC.
    1. Martinez F, Safrin S, Weycker D, Starko K, Bradford W, King T Jr, Flaherty K, Schwartz D, Noble P, Raghu G, Brown K. IPF Study Group. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142:963–967.
    1. Wells AU. Antioxidant therapy in idiopathic pulmonary fibrosis: hope is kindled. Eur Respir J. 2006;27:664–666. doi: 10.1183/09031936.06.00010006.
    1. Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J. 2008;31:1357–1367. doi: 10.1183/09031936.00171307.
    1. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, Hirani N, Hubbard R, Lake F, Millar AB, Wallace WA, Wells AU, Whyte MK, Wilsher ML. British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standard of Care Committee; Thoracic Society of Australia; New Zealand Thoracic Society; Irish Thoracic Society. Interstitial lung disease guideline. Thorax. 2008;63(Suppl 5):v1–58.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться